The global testicular cancer drugs market was valued at USD 2.41 billion in 2025 and is projected to grow from USD 2.54 billion in 2026 to USD 4.18 billion by 2034, registering a CAGR of 6.42% during the forecast period (2026–2034). The market's growth is being driven by increasing incidence of testicular cancer, rising investments in oncology...
